Immune Pharmaceuticals Inc (IMNP) financial statements (2022 and earlier)

Company profile

Business Address 1 BRIDGE PLAZA N, SUITE 270
FORT LEE, NJ 07024
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

Current Assets
Cash, cash equivalents, and short-term investments6,7762714,5436,76749172
Cash and cash equivalents6,7762714,5436,76749172
Restricted cash and investments 59312181909
Prepaid expense and other current assets116
Other current assets25531425899137
Total current assets:7,0316444,8326,8872671,197
Noncurrent Assets
Property, plant and equipment 316371414756
Intangible assets, net (including goodwill)6,4772,8063,1113,4153,607
Intangible assets, net (excluding goodwill)6,4772,8063,1113,4153,607 
Regulated entity, other noncurrent assets 400    
Restricted cash and investments    80 
Deferred costs     75
Other noncurrent assets100339370  
Other undisclosed noncurrent assets15,00014,60027,50027,52127,500 
Total noncurrent assets:21,57718,46131,35230,97731,234131
TOTAL ASSETS:28,60819,10536,18437,86431,5011,328
Current Liabilities
Accounts payable and accrued liabilities5,6896,1425,0995,9009,4331,871
Accounts payable3,5693,5222,4391,2435,1811,349
Accrued liabilities2,1202,6202,6604,1333,57257
Employee-related liabilities   488505465
Taxes payable   36175 
Derivative instruments and hedges, liabilities  84   
Liability for uncertainty in income taxes   5040 
Due to related parties266236 30469 
Deferred revenue and credits     314
Other undisclosed current liabilities   (574)(5,125)(6,501)
Total current liabilities:9,2519,1656,2867,41711,2687,801
Noncurrent Liabilities
Long-term debt and lease obligation1,4571,4942,9771,5643,359 
Long-term debt, excluding current maturities1,4571,4422,8861,5643,359 
Capital lease obligations 5291   
Liabilities, other than long-term debt4,1425,93317,39910,87010,8707,496
Deferred revenue and credits     7,496
Deferred tax liabilities, net4,1425,93310,87010,87010,870 
Derivative instruments and hedges, liabilities  6,529   
Other undisclosed noncurrent liabilities   469521 
Total noncurrent liabilities:5,5997,42720,37612,90314,7507,496
Total liabilities:14,85016,59226,66220,32026,01815,297
Temporary equity, carrying amount  1,659   
Stockholders' equity
Stockholders' equity attributable to parent, including:13,7582,5137,86317,5445,483(13,969)
Common stock213219
Treasury stock, value     (75)
Additional paid in capital127,29298,15970,84662,55027,761236,886
Accumulated other comprehensive loss     (1,130)
Accumulated deficit(113,536)(95,647)(62,986)(45,829)(22,279)(268,811)
Warrants and rights outstanding     19,152
Other undisclosed stockholders' equity attributable to parent   821  
Total stockholders' equity:13,7582,5137,86317,5445,483(13,969)
TOTAL LIABILITIES AND EQUITY:28,60819,10536,18437,86431,5011,328

Income statement (P&L) ($ in thousands)

Revenues   2197,804
Revenue, net     7,804
Cost of revenue (12,500)   (903)
Cost of goods and services sold     (903)
Gross profit: (12,500) 2196,901
Operating expenses(12,123)(14,760)(15,724)(16,668)(9,308)(8,511)
Other operating income (expense), net   (7,187)3,2511,965
Other expenses   (80)431,965
Other undisclosed operating income (loss)   7,490(2,962)(961)
Operating loss:(12,123)(27,260)(15,724)(16,363)(9,000)(606)
Nonoperating expense(28)(46)(15)  (3,380)
Debt instrument, convertible, beneficial conversion feature     (3,550)
Other nonoperating expense(28)(46)(15)   
Interest and debt expense(5,800)(1,555)(1,290)(3,404)(305)(1,199)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes(1,911)(8,656)(128)(3,783)3,5562,614
Loss from continuing operations before income taxes:(19,862)(37,517)(17,157)(23,550)(5,749)(2,571)
Income tax expense (benefit)1,9734,856  (11)(2)
Net loss attributable to parent:(17,889)(32,661)(17,157)(23,550)(5,760)(2,573)
Other undisclosed net loss available to common stockholders, basic(6,864)(7,973)(6,959)(872)(932)(3,550)
Net loss available to common stockholders, basic:(24,753)(40,634)(24,116)(24,422)(6,692)(6,123)
Convertible preferred dividends    (932)(3,550)
Net loss available to common stockholders, diluted:(24,753)(40,634)(24,116)(24,422)(7,624)(9,673)

Comprehensive Income ($ in thousands)

Net loss:(17,889)(32,661)(17,157)(23,550)(5,760)(2,573)
Comprehensive loss:(17,889)(32,661)(17,157)(23,550)(5,760)(2,573)
Other undisclosed comprehensive loss, net of tax, attributable to parent     (179)
Comprehensive loss, net of tax, attributable to parent:(17,889)(32,661)(17,157)(23,550)(5,760)(2,752)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios


Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: